Peter Mohr

Summary

Affiliation: Elbeklinikum Buxtehude
Country: Germany

Publications

  1. ncbi request reprint [Adjuvant interferon therapy in malignant melanoma]
    Peter Mohr
    Dermato Onkologie Elbe Klinikum Buxtehude, Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany
    J Dtsch Dermatol Ges 5:543-5. 2007
  2. doi request reprint [Supportive care for malignant melanoma]
    P Mohr
    Elbeklinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Deutschland
    Hautarzt 59:492-8. 2008
  3. ncbi request reprint Adjuvant therapy in melanoma
    P Mohr
    Department of Dermatology, Elbeklinikum Buxtehude, Germany
    Onkologie 26:227-33. 2003
  4. pmc Staging of cutaneous melanoma
    P Mohr
    Elbekliniken, Buxtehude, Germany
    Ann Oncol 20:vi14-21. 2009
  5. ncbi request reprint Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial
    Karsten Neuber
    Department of Dermatology, University Hospital Hamburg, Martinistr 52, D 20246 Hamburg, Germany
    Melanoma Res 13:81-5. 2003
  6. ncbi request reprint Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study
    Lutz Kowalzick
    Department of Dermatology and Allergy, Municipal Hospital Plauen, Box 100153, Germany
    Eur J Dermatol 12:558-61. 2002

Collaborators

Detail Information

Publications6

  1. ncbi request reprint [Adjuvant interferon therapy in malignant melanoma]
    Peter Mohr
    Dermato Onkologie Elbe Klinikum Buxtehude, Dermatologisches Zentrum, Am Krankenhaus 1, Buxtehude, Germany
    J Dtsch Dermatol Ges 5:543-5. 2007
  2. doi request reprint [Supportive care for malignant melanoma]
    P Mohr
    Elbeklinikum Buxtehude, Am Krankenhaus 1, 21614, Buxtehude, Deutschland
    Hautarzt 59:492-8. 2008
    ..Specific recommendations for all of these dermato-oncologic problems are provided in detail...
  3. ncbi request reprint Adjuvant therapy in melanoma
    P Mohr
    Department of Dermatology, Elbeklinikum Buxtehude, Germany
    Onkologie 26:227-33. 2003
    ..Patients with high-risk malignant melanoma should preferentially be treated in prospective randomized multicenter trials to give more detailed data for treatment recommendations...
  4. pmc Staging of cutaneous melanoma
    P Mohr
    Elbekliniken, Buxtehude, Germany
    Ann Oncol 20:vi14-21. 2009
    ....
  5. ncbi request reprint Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial
    Karsten Neuber
    Department of Dermatology, University Hospital Hamburg, Martinistr 52, D 20246 Hamburg, Germany
    Melanoma Res 13:81-5. 2003
    ..The non-haematological toxicity of this outpatient regimen was mild. In conclusion, intravenous treosulfan treatment does not induce objective response rates when used as a second-line treatment of metastatic malignant melanoma...
  6. ncbi request reprint Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study
    Lutz Kowalzick
    Department of Dermatology and Allergy, Municipal Hospital Plauen, Box 100153, Germany
    Eur J Dermatol 12:558-61. 2002
    ..In addition, rIFN-beta-1a is safe and generally well tolerated. rIFN-beta-1a represents an effective alternative treatment for BETACC...